Amicus Therapeutics (FOLD) Misses Q1 EPS by 14c

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/25/2026

1. RNG
2. DECK
3. WDC
4. BMY
5. BYD
6. SPOT
7. WCN
8. TSCO
9. BE
10. SPY

Go back to Amicus Therapeutics (FOLD) Misses Q1 EPS by 14c

Amicus Therapeutics Announces First Quarter 2015 Financial Results and Corporate Updates

May 5, 2015 4:00 PM EDT

Marketing Submissions for Migalastat Monotherapy for Fabry Disease on Track for 2Q15 in Europe and 2H15 in United States Net Cash Spend Guidance Updated to $100-$110 Million on Accelerated Commercialization and Manufacturing Next-Generation Pompe ERT Set to Enter Clinic in 2H15

CRANBURY, N.J., May 5, 2015 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD), a biopharmaceutical company at the forefront of therapies for rare and orphan diseases, today announced financial results for the first quarter ended March... More